Major drugmaker loses $27 billion in market value after failed trial
Two companies announced on Thursday that the heart disease drug they had been developing failed its Phase III trial.
AI brief
Pulse reads the full article- What happened
- Why it matters
- What to watch
Sign in to get the AI brief. Pulse explains what happened, why it matters, what to watch and who's exposed. Free for members.
Sign in to read the brief
